1. Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease

   • Phylinda L. S. Chan
   • John G. Nutt
   • Nicholas H. G. Holford

   OriginalPaper Pages: 307 - 331

2. Cluster Analysis: An Alternative Method for Covariate Selection in population Pharmacokinetic Modeling

   • Nabil Semmar
   • Bernard Bruguerolle
   • Nicolas Simon

   OriginalPaper Pages: 333 - 358

3. Pharmacodynamic Analysis of Changes in Reticulocyte Subtype Distribution in Phlebotomy-Induced Stress Erythropoiesis

   • Nidal H. Al-Huniti
   • John A. Widness
   • Peter Veng-Pedersen

   OriginalPaper Pages: 359 - 376

4. Unified Pharmacogenetics-Based Parent–Metabolite Pharmacokinetic Model Incorporating Acetylation Polymorphism for Talampanel in Humans

   • Peter Buchwald
   • Attila Juhász
   • Nicholas Bodor

   OriginalPaper Pages: 377 - 400

5. Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis

   • Aristides Dokoumetzidis
   • Leon Aarons

   OriginalPaper Pages: 401 - 418

6. Population Pharmacokinetics of the Active Metabolite of Leflunomide in Pediatric Subjects with Polyarticular Course Juvenile Rheumatoid Arthritis

   • Jun Shi
   • Steven J. Kovacs
   • Vijay O. Bhargava

   OriginalPaper Pages: 419 - 439

7. Some Considerations on the Design of Population Pharmacokinetic Studies

   • Stephen Duffull
   • Tim Waterhouse
   • John Eccleston

   OriginalPaper Pages: 441 - 457

8. Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease

   • Phylinda L. S. Chan
   • John G. Nutt
   • Nicholas H. G. Holford

   OriginalPaper Pages: 459 - 484

9. Population Pharmacokinetic–Pharmacodynamic Modeling of Subcutaneous and Pulmonary Insulin in Rats

   • Mathangi Gopalakrishnan
   • Sandra Suarez
   • Jogarao VS Gobburu

   OriginalPaper Pages: 485 - 500

10. Collapsing Mechanistic Models: An Application to Dose Selection for Proof of Concept of a Selective Irreversible Antagonist

    • Matthew M. Hutmacher
    • Debu Mukherjee
    • David C. Jordan

    OriginalPaper Pages: 501 - 520

11. Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients

    • Timothy H. Waterhouse
    • Stefanie Redmann
    • John A. Eccleston

    OriginalPaper Pages: 521 - 545

12. The Acute Disposition of (R)- and (S)-Methadone in Brain and Lung of Sheep

    • David J. R. Foster
    • Richard N. Upton
    • Allison Martinez

    OriginalPaper Pages: 547 - 570

13. The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian Approach

    • Lena E. Friberg
    • Geoffrey K. Isbister
    • Stephen B. Duffull

    OriginalPaper Pages: 571 - 605

14. A Dynamical Systems Analysis of the Indirect Response Model with Special Emphasis on Time to Peak Response

    • Lambertus A. Peletier
    • Johan Gabrielsson
    • Jacintha den Haag

    OriginalPaper Pages: 607 - 654